Organization | Chiba University

Chiba University Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Chiba Japan (1949)

Organization Overview

First Clinical Trial

2008

NCT00671489

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Chairman, Department of Psychiatry, Chiba University Graduate School of Medicine | Chiba University, Department of Neurology | Chiba University Graduate School of Medicine Department of neurology | Chiba University Hospital | Department of Child Psychiatry, Chiba University Hospital | Department of Psychiatry, Chiba University Graduate School of Medicine | Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health | Graduate School of Medicine, Chiba University | Research Center for Child Mental Development, Chiba University Graduate School of Medicine | Tadashi Hasegawa

Active Ingredients

Drugs in Phase 4 Trials (5)

cilostazol (pletal) (1 trial)

infliximab (remicade) (1 trial)

lithium (lithonate) (1 trial)

olanzapine (zyprexa) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 3 Trials (2)

icosapent ethyl (vascepa) (6 trials)

olive (1 trial)

Drugs in Phase 2 Trials (6)

eculizumab (Soliris) (1 trial)

ifenprodil (1 trial)

lacosamide (vimpat) (1 trial)

lenalidomide (revlimid) (1 trial)

tipepidine hibenzate (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Amyotrophic Lateral Sclerosis (Phase 2)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Attention Deficit and Disruptive Behavior Disorders (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Bipolar Disorder (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 2)

Disease (Phase 2)

Granulomatosis with Polyangiitis (Phase 4)

Hyperkinesis (Phase 2)

Hypertriglyceridemia (Phase 3)

Mental Disorders (Phase 2)

Microscopic Polyangiitis (Phase 4)

Motor Neuron Disease (Phase 2)

POEMS Syndrome (Phase 2)

Problem Behavior (Phase 2)

Sclerosis (Phase 2)

Stress Disorders, Post-Traumatic (Phase 3)

Stress Disorders, Traumatic (Phase 3)

Syndrome (Phase 2)

Vasculitis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 17
# of Trial APIs: 13